Mallinckrodt — Debt Investor Presentation (April 2022)
46 slides from Mallinckrodt's debt investor presentation, Apr 14, 2022
Slide 1: Mallinckrodt Pharmaceuticals Company Presentation April 2022
Mallinckrodt Pharmaceuticals Company Presentation APRIl 2022 Exhibit 99.1
Slide 2: Disclaimer: Notice to and Undertaking by Recipients
2 Disclaimer Notice to and Undertaking by Recipients This Company Presentation (the "Company Presentation") has been prepared solely for informational purposes from information supplied by or on behalf of Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies
Slide 3: Disclaimer (Cont'd): Forward-Looking Statements
IMPORTANT INFORMATION: This document contains forward-looking statements which refer to proposed activities and aspirational brand goals which may occur in the future. References in this document to any proposed new device, indication, condition or other therapeutic area are intended to refer to pot
Slide 4: Disclaimer (Cont'd): Non-GAAP Financial Measures
4 Disclaimer (Cont’d) Non-GAAP Financial Measures This document contains financial measures, such as adjusted EBITDA, net debt, net leverage, segment operating margin, free cash flow, free cash flow conversion, adjusted gross margin, adjusted net sales, total 1st lien leverage, net 1st lien leverage
Slide 5: Agenda
5 Agenda 1 Executive Summary 2 Key Credit Highlights 3 Company Overview 4 Financial Overview 5 Appendix
Slide 6: Executive Summary
6 Section 1 Executive Summary Sub title text goes here
Slide 7: Executive Summary: Company Overview and Bankruptcy Status
Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland (“Mallinckrodt” or the “Company”) is a diversified global specialty pharmaceutical company, operating in two segments: (1) Specialty Brands, which includes the critical care and autoim
Slide 8: Executive Summary: Bankruptcy Update
Executive Summary 8 Bankruptcy Update Opioid Settlement For more than two years, Mallinckrodt has engaged in settlement discussions with the Opioid Plaintiffs To prevent years of unsustainable litigation and potential tens of billions of judgments, the emergence plan permanently resolves Opioid liti
Slide 9: Sources & Uses and Pro Forma Capitalization
Executive Summary 9 Sources & Uses and Pro Forma Capitalization Note: Assumes an illustrative emergence as of June 30, 2022; actual emergence date may materially differ Represents cash adjustment from estimated pre-emergence cash balance of $1,312MM to get to a Pro-Forma cash balance of $482MM $15MM
Slide 10: Key Credit Highlights
10 Section 2 Key Credit Highlights Sub title text goes here
Slide 11: Key Credit Highlights
Key Credit Highlights 11 Key Credit Highlights Diversified Global Specialty Pharma Company High Level of Forward Visibility in Core Legacy Brands Improved Financial Position and Disciplined Approached to Capital Allocation Attractive Margins and Robust Free Cash Flow Generation API and Generics Busi
Slide 12: Diversified Global Specialty Pharma Company
Notes: Includes Ofirmev, Rescula, Innocoll and contract manufacturing revenues Includes opioids, ADHD, addiction treatment, international non-promoted brands and other Includes ADHD, addiction treatment, international non-promoted brands and other Key Credit Highlights 12 Diversified Global Specialt
Slide 13: High Level of Forward Visibility in Core Legacy Brands
Key Credit Highlights 13 High Level of Forward Visibility in Core Legacy Brands HC Product Description Background ’21A Sales Historical Performance Expected Net Sales in ‘26 Outlook Commentary Injectable treatment for people living with certain chronic inflammatory or autoimmune conditions 19 indica
Slide 14: API and Generics Business Serving Critical Needs of Patients
Key Credit Highlights 14 API and Generics Business Serving Critical Needs of Patients Global leader in acetaminophen production, controlled substances, addiction treatment, and ADHD, with vertically-integrated manufacturing ensuring quality and consistency of supply 5 Award-winning cGMP U.S.-based m
Slide 15: Positioned for Growth From Product Launches and Critical Care Pipeline
Key Credit Highlights 15 Positioned for Growth From Near-Term Product Launches And Late-Stage Critical Care Pipeline Launched in January 2022 Net Sales Opportunity: >$150MM (1) Launch anticipated in 1H 2023 (2) Net Sales Opportunity: >$200MM (1) Near-term growth anticipated from StrataGraft and Terl
Slide 16: Resolved Key Legacy Litigation Overhang
Key Credit Highlights 16 Resolved Key Legacy Litigation Overhang and Refocused on Providing Critical Medicines to Patients Resolution of Opioid Litigation Resolution of Key Acthar Litigation Post-emergence, Mallinckrodt will have resolved all key litigation issues Opioid litigation resolved through
Slide 17: Attractive Margins and Robust Free Cash Flow Generation
Active management of cost structure has allowed the Company to maintain margin profile In light of net sales performance, management accelerated cost savings plans, reducing SG&A by ~$150MM compared to 2020 by focusing on: Specialty Brands: realignment of general manager model, reduction in overall
Slide 18: Improved Financial Position and Disciplined Capital Allocation
Key Credit Highlights 18 Improved Financial Position and Disciplined Approach to Capital Allocation Strong liquidity upon emergence, supported by a healthy cash balance, undrawn AR ABL facility, and robust cash flows Potential to explore sale of non-core assets to enable further deleveraging Committ
Slide 19: Highly Experienced Management Team and Refreshed Board
Key Credit Highlights 19 New post-reorganization board with significant industry and restructuring experience Highly Experienced Management Team and Refreshed Board of Directors Paul M. Bisaro, Chairman Former Executive Chairman, Amneal Pharmaceuticals Daniel Celentano, Director Former Senior Managi
Slide 20: Anti-Diversion Efforts and ESG Strategy
Reinforcing Historical Efforts Establishing Future Anti-Diversion Efforts Mallinckrodt has worked closely with various law enforcement agencies throughout the United States to combat opioid diversion and abuse Mallinckrodt has sponsored drug take-back programs designed to collect unused medications
Slide 21: Company Overview
21 Section 3 Company Overview Sub title text goes here
Slide 22: Introduction to Mallinckrodt
Company Overview 22 Introduction to Mallinckrodt Founded in 1867 2,800+ Employees Worldwide 20+ Drug Development Programs 2 Segments: Specialty Brands and Specialty Generics 4 Core Values: Patient-Centric Integrity Innovative Collaborative Managing Complexity. Improving Lives. Mallinckrodt is an inn
Slide 23: Primary Focus on Underserved Patients With Severe and Critical Conditions
Company Overview 23 Our Primary Focus Remains on Improving Outcomes For Underserved Patients With Severe and Critical Conditions Our Vision Innovation-driven biopharmaceutical company… …focused on improving outcomes for underserved patients… …with severe and critical conditions … …adding value throu
Slide 24: Our Go Forward Strategy
Company Overview 24 Our Go Forward Strategy Optimizing Focus on Critical Care Realigning Cost Structure Maximize Free Cash Flow Deleverage Over Long Term Refocusing on mission as an innovative biopharmaceutical company focused on underserved patients Optimize development focus on Critical Care oppor
Slide 25: Acthar is a Tried and Tested Critical Medicine
Company Overview 25 Acthar is a Tried and Tested Critical Medicine Used in 19 Indications Including Infantile Spasms Naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides that is indicated in multiple therapeutic areas including rheumatology, ophthalmo
Slide 26: INOmax is a Life-Saving Neonatal Respiratory Therapy System
Notes: Includes babies born in or transferred to hospitals with access to INOmax Investigational product. Safety and efficacy have not yet been established by FDA. Company Overview 26 INOmax is a Life-Saving Neonatal Respiratory Therapy System TBU – INOmax tearsheet + some detail on INOmax Evolve Va
Slide 27: Therakos is the Only Approved ECP System
Company Overview 27 Therakos is the Only Approved ECP System and Consumable used for Palliative Treatment of Skin Manifestations of CTCL TBU – Therakos tearsheet Immunotherapy treatment platform that enhances the ability of a patient’s immune system to fight disease via the world’s only fully-integr
Slide 28: StrataGraft is a Recently-Launched Regenerative Skin Tissue
Company Overview 28 Stratagraft is a Recently-Launched, FDA-Approved Regenerative Skin Tissue Indicated For the Treatment of Severe Burns TBU – Stratagraft tearsheet Allogeneic cellularized scaffold product indicated for the treatment of adults with thermal burns containing intact dermal elements fo
Slide 29: Terlivaz Could Provide First Indicated US Treatment for HRS Type-1
Notes: Investigational product. Safety and efficacy have not yet been established by FDA. National Organization for Rare Disorders. Hepatorenal Syndrome Open Access Journal of Clinical Trials Journal of Investigative Medicine United States Census Bureau National Review Expert Review of Gastroenterol
Slide 30: Conditions Representing Growth Opportunities in the Hospital
ICU = Intensive Care Unit, AMC = Academic Medical Centers, KOL = Key Opinion Leaders, HEOR = Health Economics Outcomes Research Company Overview 30 We Have Identified Several Conditions that Represent Growth Opportunities, Most of Which are Delivered in the Hospital Chronic treatments initiated and
Slide 31: Hospital and Reimbursement Market Trends
Hospital margins continue to decline Increasing consolidation under IDNs or systems Greater institutional control over prescribing decisions, taking away decision-making from hospital physicians Continued push to shift from inpatient care to less expensive care settings Value-based reimbursement mak
Slide 32: Distinct Capabilities and Customer / Patient Services
HCP = Healthcare Professionals, PBM = Pharmacy Benefit Manager Company Overview 32 Our Distinct Capabilities and Customer / Patient Services Position Us to Effectively Navigate Complexities Across Care Settings Further Enabling Capability & Services Across Point of Care Existing Mallinckrodt Capabil
Slide 33: Advanced R&D Capabilities Across All Phases of Development
Company Overview 33 Advanced R&D Capabilities Across all Phases of Development Research Diverse experience in chemistry, CMC/formulations and pre-clinical science including in vivo & in vitro cell and molecular biology Clinical Development Scientific leadership, biometrics, data management and opera
Slide 34: Mallinckrodt's Development Pipeline
HNS = Hepatorenal Syndrome, DPT = Deep Partial Thickness, GVHD = Graft vs Host Disease, FT = Full Thickness, RNAi = RNA Interference Notes: Terlivaz launch assumed in Q1 2023 Collaboration with Silence Therapeutics; options exercised on 3 complement targes Target not disclosed Company Overview 34 Ma
Slide 35: Specialty Generics is a Unique, Vertically Integrated Business
Company Overview 35 Specialty Generics is a Unique, Vertically Integrated Business Tangible benefits of vertical integration Differentiated R&D Capabilities and Pipeline of Opportunities in Development Niche U.S.-based specialty generics business Industry-leading reputation for quality and service S
Slide 36: Specialty Generics 2021 Performance and Outlook
2021 Performance $662MM net sales; decline of 4% from 2020 Gain/stabilization of share across all finished dose segments Market value declines accelerated in ADHD finished dose, impacting year Investments into APAP business expansions Sustained relationships with primary customers across business bu
Slide 37: Vertically Integrated U.S.-based Manufacturing Infrastructure
Company Overview 37 Vertically Integrated, High Quality, U.S.-based Manufacturing Infrastructure St. Louis, MO Multi-purpose API facility with manufacture and Lifecycle Science for complex small molecules Greenville, IL Compressible acetaminophen facility Hobart, NY Complex generics facility Raleigh
Slide 38: Among the World's Largest Producers of Bulk Acetaminophen
Company Overview 38 Among the World’s Largest Producers of Bulk Acetaminophen Mallinckrodt Pharmaceuticals operates the only US-based manufacturing location for acetaminophen/paracetamol, the active ingredient in Tylenol® and over 600 different OTC and Rx medicines Acetaminophen is the leading over-
Slide 39: Specialty Generics' Strategy Focuses on Maximizing Value
Company Overview 39 Specialty Generics’ Strategy Focuses on Maximizing Value API + Generics Maintain base business with superior quality and customer service Capture additional market opportunities Restore strategic inventory levels Advance current ANDA pipeline to diversify the business Enhance bus
Slide 40: Financial Overview
Section 4 Financial Overview
Slide 41: Disciplined and Conservative Financial Policy Post-Emergence
Following emergence from bankruptcy, Mallinckrodt will have a disciplined and conservative financial policy, focused on rapid deleveraging and executing a clearly defined business plan Committed to conservative, balanced financial policies Immediate focuses are deleveraging and investing in the busi
Slide 42: Historically Stable Margin Profile and 2021 Performance Overview
Attractive and historically stable gross margin and Adj. EBITDA margin profile Relatively low CapEx spending drives robust free cash flow conversion trends Recent performance impacted by bankruptcy disruptions 2021 Performance Overview Specialty Brands adversely impacted by entrance of generic compe
Slide 43: Appendix: Supplemental Materials
Appendix Supplemental Materials
Slide 44: Summary Plan Treatment
Company Overview The confirmed Plan features the following treatments by class: Summary Plan Treatment 44 Summary Plan Treatment Revolver Repayment in full in cash Term Loans At the Debtors’ option, either (a) New Takeback Term Loans, plus 1.0% exit fee, or (b) repayment in full in cash, plus 0.5% e
Slide 45: Summary Plan Treatment (cont'd)
Company Overview Summary Plan Treatment (cont’d) 45 Summary Plan Treatment Trade Claims Up to $50MM Trade Claim Cash Pool Acthar Plaintiffs: CMS, DOJ, Government $260MM of structured cash payments over 7 years: $15MM at emergence and 1st anniversary, $20MM on 2nd and 3rd anniversaries, $32.5MM on 4t
Slide 46: Non-GAAP Reconciliation Notes
Notes: Includes $2.1 million and $12.3 million of accelerated depreciation in SG&A related to restructuring charges incurred during fiscal 2021 and 2020, respectively Fiscal 2021 includes a $125.0 million charge related to the opioid-related litigation settlement liability and a $34.3 million increa
Mallinckrodt — Debt Investor Presentation (April 2022) on 6ix